ReviewTranslational lung cancer research2016
Targeting angiogenesis in small cell lung cancer.
Review in Translational lung cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of immunotherapy or antiangiogenic agent-based treatment strategies versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer.Cancer medicine · 2019Pooled it
- Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.Thoracic cancer · 2021Trial
- Timing, fractionation, and dose of thoracic radiotherapy in patients with extensive-stage small cell lung cancer undergoing first-line Chemo-Immunotherapy.Clinical and translational radiation oncology · 2026Article
- Advancements in extensive-stage small cell lung cancer therapy: from molecular profiling to the advent of precision oncology.Frontiers in immunology · 2025Review
- Review
- Alterations in Peripheral Lymphocyte Subsets under Immunochemotherapy in Stage IV SCLC Patients: Th17 Cells as Potential Early Predictive Biomarker for Response.International journal of molecular sciences · 2024Article
- Assessment of Naples prognostic score in predicting survival for small cell lung cancer patients treated with chemoradiotherapy.Annals of medicine · 2023Article
- Preventive and therapeutic effects of green tea on lung cancer: a narrative review of evidence from clinical and basic research.Journal of thoracic disease · 2022Review
- Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies.Cancer reports (Hoboken, N.J.) · 2022Review
- Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.Journal of cancer research and clinical oncology · 2022Article
- Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).The oncologist · 2022Article
- Optimal regulation of tumour-associated neutrophils in cancer progression.Royal Society open science · 2022Article
- Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.Clinical Medicine Insights. Oncology · 2022Article
- Recapitulating the Angiogenic Switch in a Hydrogel-Based 3D In Vitro Tumor-Stroma Model.Bioengineering (Basel, Switzerland) · 2021Article
- Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.International journal of clinical oncology · 2021Article
- PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses.Cancers · 2021Review
- Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer.International journal of general medicine · 2021Article
- Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies.Frontiers in oncology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) is a highly aggressive and lethal malignancy. Despite high initial response rates to systemic chemotherapy, the disease eventually relapses; further treatment only modestly improves outcomes and overall survival (OS) for patients with extensive stage disease is less than one year. Little progress has been made during the past decades, with no new drugs approved. Consequently, the development of novel strategies is an unmet need. The inhibition of angiogenesis, a defining characteristic of cancer, has demonstrated modest efficacy in several human malignancies, including non-small cell lung cancer (NSCLC). However, results from clinical trials in SCLC have been disappointing, and no anti-angiogenic agent has received regulatory approval due to lack of clinical efficacy. The elucidation of underlying mechanisms responsible for tumor resistance to angiogenic therapy and the simultaneous blockade of multiple elements that play a role in angiogenesis need to be further explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.